SCHEMBL8422243

SCHEMBL8422243

CCOC(=O)N1Cc2cccc(F)c2C1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP8 Q6V1X1 2/20 0.59
DPP9 Q86TI2 2/20 0.59
DPP7 Q9UHL4 2/20 0.59
ALDH1A1 P00352 6/20 0.55
KDM4E B2RXH2 3/20 0.55
TRAP1 Q12931 5/20 0.50
POLB P06746 1/20 0.50
ALOX15 P16050 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
HSP90B1 P14625 2/20 0.48
LMNA P02545 1/20 0.47
ABHD6 Q9BV23 2/20 0.46
MAPT P10636 2/20 0.45
MEN1 O00255 1/20 0.45
MAPK1 P28482 1/20 0.45
RAB9A P51151 1/20 0.45
MDM2 Q00987 1/20 0.45
KMT2A Q03164 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
BRD4 O60885 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6886590 0.84 DPP8 (0.54) DPP8DPP9DPP7TRAP1HSP90B1
SCHEMBL3478866 0.83 DPP8 (0.60) DPP8DPP9DPP7TRAP1HSP90B1
SCHEMBL9757421 0.82 KMT2A (0.46) DPP8DPP9DPP7ALDH1A1KDM4E
SCHEMBL6677698 0.82 NOTUM (0.57) DPP8DPP9DPP7ALDH1A1POLB
SCHEMBL13712937 0.82 DPP8 (0.62) DPP8DPP9DPP7TRAP1HSP90B1
SCHEMBL8404042 0.81 NOTUM (0.61) DPP8DPP9DPP7TRAP1HSP90B1
SCHEMBL3427494 0.81 DPP8 (0.57) DPP8DPP9DPP7TRAP1HSP90B1
SCHEMBL8221404 0.81 DDB1 (0.55) DPP8DPP9DPP7TRAP1HSP90B1
SCHEMBL9757419 0.79 KDM4E (0.51) ALDH1A1KDM4ELMNAMAPTMEN1
SCHEMBL497487 0.79 TRAP1 (0.56) DPP8DPP9DPP7TRAP1HSP90B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8377872-B2 Non-structural protein-3 (NS-3) protease inhibitors; viricides ENANTA PHARMACEUTICALS, INC. (US) 2013-02-19 US disclosed
US-7605126-B2 Acylaminoheteroaryl hepatitis C virus protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2009-10-20 US disclosed
US-20090197888-A1 FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2009-08-06 US disclosed
US-20090186869-A1 Antiviral compounds GILEAD SCIENCES, INC. (US) 2009-07-23 US disclosed
US-20090123423-A1 HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR ENANTA PHARMACEUTICALS, INC. 2009-05-14 US disclosed
US-20080287449-A1 AZA-TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2008-11-20 US disclosed
US-20080274080-A1 AZA-PEPTIDE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2008-11-06 US disclosed
US-20080267916-A1 CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2008-10-30 US disclosed
US-20080039470-A1 Acylaminoheteroaryl hepatitis C virus protease inhibitors ENANTA PHARMACEUTICALS, INC. 2008-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080039470-A1 Acylaminoheteroaryl hepatitis C virus protease inhibitors ATG4A, CYP4A22, AADAC DPP8 47/4885DPP9 123/4885DPP7 49/4885
US-20090186869-A1 Antiviral compounds MAVS, EIF2AK2, ZC3HAV1 DPP8 148/4885DPP9 179/4885DPP7 176/4885
US-20080287449-A1 AZA-TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS CTSC, DPP4, ANPEP DPP8 16/4885DPP9 18/4885DPP7 14/4885
US-20090123423-A1 HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR HPN, PRSS1, SERPINB1 DPP8 139/4885DPP9 201/4885DPP7 156/4885
US-20090197888-A1 FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS CTSC, PRSS1, SPINT2 DPP8 34/4885DPP9 31/4885DPP7 41/4885
US-20080274080-A1 AZA-PEPTIDE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS VIP, CTSC, PRSS1 DPP8 15/4885DPP9 19/4885DPP7 12/4885
US-20080267916-A1 CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS PRSS1, CTSC, PREP DPP8 35/4885DPP9 48/4885DPP7 36/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.